AU2001271163A1 - Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition - Google Patents

Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Info

Publication number
AU2001271163A1
AU2001271163A1 AU2001271163A AU7116301A AU2001271163A1 AU 2001271163 A1 AU2001271163 A1 AU 2001271163A1 AU 2001271163 A AU2001271163 A AU 2001271163A AU 7116301 A AU7116301 A AU 7116301A AU 2001271163 A1 AU2001271163 A1 AU 2001271163A1
Authority
AU
Australia
Prior art keywords
androgen
tamoxifen
providing
pharmaceutical combination
aromatase inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271163A
Inventor
Ian Cockshott
Barrington Furr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016428A external-priority patent/GB0016428D0/en
Priority claimed from GB0020767A external-priority patent/GB0020767D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001271163A1 publication Critical patent/AU2001271163A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
AU2001271163A 2000-07-05 2001-07-04 Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition Abandoned AU2001271163A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0016428 2000-07-05
GB0016428A GB0016428D0 (en) 2000-07-05 2000-07-05 Pharmaceutical combination
GB0020767 2000-08-24
GB0020767A GB0020767D0 (en) 2000-08-24 2000-08-24 Pharmaceutical combination
PCT/SE2001/001548 WO2002002099A1 (en) 2000-07-05 2001-07-04 Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Publications (1)

Publication Number Publication Date
AU2001271163A1 true AU2001271163A1 (en) 2002-01-14

Family

ID=26244591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271163A Abandoned AU2001271163A1 (en) 2000-07-05 2001-07-04 Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

Country Status (5)

Country Link
US (1) US20030158160A1 (en)
EP (1) EP1324754A1 (en)
JP (1) JP2004501967A (en)
AU (1) AU2001271163A1 (en)
WO (1) WO2002002099A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
ES2305350T3 (en) * 2001-11-29 2008-11-01 Gtx, Inc. PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY THE PRIVACY OF ANDROGENS.
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (en) * 1978-04-17 1979-10-25 Schering Ag USE OF ANTIOESTROGEN AND ANTIGONADOTROP ACTING ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
CA2632790A1 (en) * 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders

Also Published As

Publication number Publication date
EP1324754A1 (en) 2003-07-09
JP2004501967A (en) 2004-01-22
WO2002002099A1 (en) 2002-01-10
US20030158160A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2001284690A1 (en) Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2
EP1085848A4 (en) Inhibitors of transcription factor nf-kappa b
AU4903600A (en) An insulating construction form and manner of employment for same
EP1411959A4 (en) Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
SI1423381T1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IT1298131B1 (en) DISPENSER OF PASTOSE OR CREAMY SUBSTANCES
AU6465400A (en) Inhibition of action potentials
HUP0201872A3 (en) Steroid compounds and pharmaceutical compositions of the same
AU2001271163A1 (en) Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001244221A1 (en) Shower partition and shaped section for the same
IL152545A0 (en) Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
IL140324A0 (en) Inhibition of transcription factor nf-kb
PT1140110E (en) CLAIMS OF DEHYDROEPIANDROSTERONE AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS
AUPQ629000A0 (en) Inhibition of fungi
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2001262834A1 (en) Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
IL164556A0 (en) Systemic marker for mointoring anti-inflammatory and antioxidant actions of therapeutic agents
AU2001268001A1 (en) Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
AU2001271162A1 (en) Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
AU2003265281A1 (en) Methods and compositions for the enhancement of wound healing
AU6800101A (en) Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition